Marshall Wace
SYRE icon

Marshall Wace’s Spyre Therapeutics SYRE Stock Holding History

Marshall Wace’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88M Buy
991,693
+852,434
+612% +$62.2M 0.07% 230
2026
Q1 		$7.02M Buy
+139,259
New +$5.25M 0.01% 1135
2024
Q2 		– Sell
-161,921
Closed -$6.14M – 2946
2024
Q1 		$6.14M Buy
161,921
+141,669
+700% +$4.1M 0.01% 919
2023
Q4 		$436K Buy
+20,252
New +$279K ﹤0.01% 1762
2022
Q2 		– Sell
-6,167
Closed -$355K – 3831
2022
Q1 		$355K Buy
6,167
+4,502
+270% +$378K ﹤0.01% 2919
2021
Q4 		$197K Sell
1,665
-10,968
-87% -$1.73M ﹤0.01% 3160
2021
Q3 		$2.51M Sell
12,633
-13,423
-52% -$2.35M 0.01% 1387
2021
Q2 		$4.53M Sell
26,056
-21,594
-45% -$3.92M 0.02% 897
2021
Q1 		$9.44M Sell
47,650
-2,080
-4% -$399K 0.04% 483
2020
Q4 		$9.78M Buy
49,730
+33
+0.1% +$6.84K 0.05% 357
2020
Q3 		$8.81M Sell
49,697
-260
-0.5% -$48.1K 0.06% 339
2020
Q2 		$11.6M Buy
49,957
+16,391
+49% +$3.12M 0.08% 246
2020
Q1 		$3.91M Buy
33,566
+230
+0.7% +$39.1K 0.04% 448
2019
Q4 		$6.37M Buy
33,336
+1,312
+4% +$258K 0.04% 450
2019
Q3 		$6.16M Buy
32,024
+5,676
+22% +$1.11M 0.05% 439
2019
Q2 		$4.51M Buy
26,348
+11,312
+75% +$1.96M 0.04% 523
2019
Q1 		$3.03M Buy
+15,036
New +$3.13M 0.03% 626

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Marshall Wace's SYRE Position: Q2 2026 in Review

Marshall Wace increased its Spyre Therapeutics (SYRE) stake by 612% in Q2 2026, buying an estimated $62.2M and bringing the position to 991,693 shares worth $88M. The position accounts for 0.07% of the portfolio, ranked #230.

Marshall Wace first reported a position in SYRE in Q1 2019 and has held it in 17 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Marshall Wace held 991,693 shares of Spyre Therapeutics worth $88M as of Q2 2026.
  • Marshall Wace bought 852,434 Spyre Therapeutics shares in Q2 2026, an estimated $62.2M.
  • Spyre Therapeutics made up 0.07% of Marshall Wace's portfolio in Q2 2026, its #230 holding.
  • Marshall Wace first reported a position in Spyre Therapeutics in Q1 2019 and has held it in 17 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.